UTMD vs. ARAY, TELA, SPNE, CTSO, CODX, ATRI, ANIK, OSUR, CERS, and WST
Should you be buying Utah Medical Products stock or one of its competitors? The main competitors of Utah Medical Products include Accuray (ARAY), TELA Bio (TELA), SeaSpine (SPNE), Cytosorbents (CTSO), Co-Diagnostics (CODX), Atrion (ATRI), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Cerus (CERS), and West Pharmaceutical Services (WST). These companies are all part of the "surgical & medical instruments" industry.
Utah Medical Products (NASDAQ:UTMD) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
Utah Medical Products has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
Accuray received 179 more outperform votes than Utah Medical Products when rated by MarketBeat users. Likewise, 65.67% of users gave Accuray an outperform vote while only 61.29% of users gave Utah Medical Products an outperform vote.
In the previous week, Accuray had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 6 mentions for Accuray and 3 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.19 beat Accuray's score of 0.49 indicating that Utah Medical Products is being referred to more favorably in the media.
69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 6.6% of Utah Medical Products shares are owned by company insiders. Comparatively, 3.8% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Accuray has a consensus target price of $8.25, indicating a potential upside of 378.26%. Given Accuray's higher possible upside, analysts plainly believe Accuray is more favorable than Utah Medical Products.
Utah Medical Products has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
Utah Medical Products has a net margin of 33.40% compared to Accuray's net margin of -4.99%. Utah Medical Products' return on equity of 13.06% beat Accuray's return on equity.
Summary
Utah Medical Products beats Accuray on 10 of the 17 factors compared between the two stocks.
Get Utah Medical Products News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Utah Medical Products Competitors List
Related Companies and Tools
